Mammoth Biosciences disclosed nonhuman primate data for its lead in vivo gene‑editing program aimed at lowering triglycerides, and announced plans for a first human trial. The company reported durable triglyceride reductions in monkeys following a single administration of their candidate gene‑editing approach. Mammoth said the data support clinical translation and will inform dosing and safety planning for the upcoming trial. The program is notable as another contender using CRISPR‑derived editing modalities to target metabolic endpoints via liver delivery.